Professor of Oncology, Professor of Medicine, Johns Hopkins University School of Medicine; Director, Medical Oncology/Hematogy Fellowship Training Program, Director, Division of Medical Oncology
Oncology
Dr. Ross C. Donehower, MD
Ross C. Donehower, MD works in the field of Oncology. He went to University of Minnesota Medical School. University of Minnesota Medical School is ranked 40/10 in Research/PrimaryCare. He has 9 awards "America's Top Doctors", "CMS Meaningful Use Stage 1 Certification", "America's Top Doctors for Cancer", "Top Doctors:Baltimore Area", "Top Doctors:Washington-Baltimore", "Fellow (FASCO)", "Men's Health", "Super Doctor" and "Top MD". Ross C. Donehower has written publications. He has 33 publications published with PubMed. The lastest publication is: 'A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.' Ross Donehower accepts Medicare.
Publications
- A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.
- Familial GI Stromal Tumor With Loss of Heterozygosity and Amplification of Mutant KIT.
- Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer.
- Correlation of smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenoca...
- Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for coloRectal metastases.
- Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic Cancer.
- Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic Cancer.
- Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal Cancer.
- Randomized Phase III Multi-Institutional Study of TNFerade Biologic With Fluorouracil and Radiotherapy for Locally Advanced Pancreatic Cancer: Final Results.
- A multicenter Analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
- Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal Cancer.
- Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic Cancer.
- Make quality Cancer survivorship care possible in the era of workforce shortage.
- A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic Cancer.
- A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid Tumors.
- Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid Tumors.
- Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid Tumors.
- Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common Bile duct.
- Adjuvant concurrent chemoradiation for node-positive adenoCarcinoma of the duodenum.
- Phase II study of erlotinib in patients with advanced biliary Cancer.
- Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid Tumors.
- Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular Cancer.
- A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid Tumors.
- Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
- Temozolomide in patients with advanced Cancer: phase I and pharmacokinetic study.
- Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile.
- Is HIF-1 alpha a valid therapeutic target?
- A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced Cancer.
- Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.
- Role of body surface area in dosing of investigational antiCancer agents in adults, 1991-2001.
- Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute Myeloid leukemia.
- Evolving therapies: farnesyltransferase inhibitors.
Schools
University of Mn Med Sch
Johns Hopkins Hospital
National Institute Of Health
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors for Cancer
- Top Doctors:Baltimore Area
- Top Doctors:Washington-Baltimore
- Fellow (FASCO)
- Men's Health
- Super Doctor
- Top MD
Education
-
Johns Hopkins University
-
University of Minnesota Medical School
Hospital
-
Johns Hopkins Hospital
-
Johns Hopkins Bayview Medical Center
Drug Facts
| NPI NUMBER |
|
1780631713 |
| NPPES Provider LastName |
|
DONEHOWER |
| NPPES Provider FirstName |
|
ROSS |
| NPPES Provider ZIPCode |
|
210934515 |
| NPPES Provider State |
|
MD |
| Specialty Description |
|
Medical Oncology |
| Total Claim Count |
|
108.0 |
| Distinct Opioid Count |
|
0.0 |
| Opioid Claim Count |
|
0.0 |
| Percent Opioid Claims |
|
0.0 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1780631713 |
| Last Name Of The Provider |
DONEHOWER |
| First Name Of The Provider |
ROSS |
| View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.
This doctor has more publications